Pictet Asset Management
ALNY icon

Pictet Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pictet Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.5M Sell
237,920
-78,133
-25% -$26.6M 0.08% 246
2025
Q4 		$126M Sell
316,053
-71,493
-18% -$31.6M 0.12% 189
2025
Q3 		$176M Sell
387,546
-77,060
-17% -$31.4M 0.17% 143
2025
Q2 		$151M Sell
464,606
-16,361
-3% -$4.53M 0.15% 158
2025
Q1 		$130M Buy
480,967
+50,355
+12% +$12.9M 0.14% 167
2024
Q4 		$101M Sell
430,612
-234,110
-35% -$61.6M 0.11% 202
2024
Q3 		$183M Sell
664,722
-93,806
-12% -$24.4M 0.2% 132
2024
Q2 		$184M Sell
758,528
-202,976
-21% -$32M 0.21% 116
2024
Q1 		$145M Buy
961,504
+75,919
+9% +$12.7M 0.16% 168
2023
Q4 		$170M Buy
885,585
+94,830
+12% +$16.2M 0.19% 138
2023
Q3 		$140M Buy
+790,755
New +$151M 0.17% 158

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management's ALNY Position: Q1 2026 in Review

Pictet Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 25% in Q1 2026, selling an estimated $26.6M and leaving 237,920 shares worth $77.5M. The position accounts for 0.08% of the portfolio, ranked #246.

Pictet Asset Management first reported a position in ALNY in Q3 2023 and has held it in 11 quarters since. The position peaked at $184M in Q2 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Pictet Asset Management held 237,920 shares of Alnylam Pharmaceuticals worth $77.5M as of Q1 2026.
  • Pictet Asset Management sold 78,133 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $26.6M.
  • Alnylam Pharmaceuticals made up 0.08% of Pictet Asset Management's portfolio in Q1 2026, its #246 holding.
  • Pictet Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Pictet Asset Management's Alnylam Pharmaceuticals position peaked at $184M in Q2 2024.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Pictet Asset Management's 13F filing for Q1 2026, filed 22 Apr 2026.